FORM I	PTO-139	0 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER										
(**** I		RANSMITTAL LETTER TO THE UNITED STATES	2039-0156P										
		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR											
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 U.S. APPLICATION NO. (IF KNOW) 10/0193													
INTE	RNAT	IONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED										
TITLE		PCT/EP00/06087 29 June 2000 NVENTION	29 June 1999										
USE OF HYALURONIC ACID DERIVATIVES IN PHARMACEUTICAL PREPARATIONS AND BIOMATERIALS													
		E PREVENTION AND TREATMENT OF CUTANEOUS SCARS											
APPLICANT(S) FOR DO/EO/US													
DALLE CARBONARE, Maurizio													
CALLEGARO, Lanfranco													
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:													
1.	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.											
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.											
3.	\boxtimes	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.											
4.	\boxtimes	The US has been elected by the expiration of 19 months from the priority date (Article 31).											
5.													
		a. 🗵 is attached hereto (required only if not communicated by the International Communicated by the International Communicated States and Communicate	tional Bureau).										
₹.		b. 🛮 has been communicated by the International Bureau.											
		c. \square is not required, as the application was filed in the United States Recei	iving Office (RO/US).										
i 6.		An English language translation of the International Application as filed (35 U	.S.C. 371(c)(2)).										
	a. is attached hereto.												
8-		b. \square has been previously submitted under 35 U.S.C. 154(d)(4).											
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article	19 (35 U.S.C. 371 (c)(3))										
•		a. \square are attached hereto (required only if not communicated by the Internal	itional Bureau).										
		b. \square have been communicated by the International Bureau.											
	•	c. \square have not been made; however, the time limit for making such amendments has NOT expired.											
		d. 🛮 have not been made and will not be made.											
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).											
9. 10.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).											
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).											
11.	\boxtimes	A copy of the International Preliminary Examination Report (PCT/IPEA/409).											
12.	\boxtimes	A copy of the International Search Report (PCT/ISA/210).											
It	ems 1	3 to 20 below concern document(s) or information included:											
13.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.											
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.											
15.	\boxtimes	A FIRST preliminary amendment.											
16.		A SECOND or SUBSEQUENT preliminary amendment.											
17.		A substitute specification.											
18.		A change of power of attorney and/or address letter.											
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.											
20.		A second copy of the published international application under 35 U.S.C. 154(d)(4).											
21.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).											
22. 23.	⊠ ⊠	Certificate of Mailing by Express Mail Other items or information:											
23.													
,		One (1) Sheet of Formal Drawings Application Data Sheet	·										

U.S. A	FFLICA	L	"0"/0"19	387	PCT/E	P00/0608				9-0156P	
24	T	he foll	owing fees are subr	nitted:.		_			CALCULATION	S PTO USE ONLY	
	international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO							40.00			
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO								·		
	☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO								\$740.00		
	but all	claims	s did not satisfy pro	10.00							
	and all	ational claim	s satisfied provision	s of PCT Art	CFR 1.482) paid to Uicle 33(1)-(4)			00.00			
					ATE BASIC FE				\$890.00		
months	from	\$130.0 the ear	0 for furnishing the liest claimed priorit	y date (37 C)	FR 1.492 (e)).	□ 20			\$130.00		
CLAIMS			NUMBER :		NUMBER EXT	'RA	RAT		*******		
Total c			28	- 20 =	8		x \$18.		\$144.00		
	ndent c		4	- 3=	1	x \$84.00			\$84.00		
Multip	le Depo	endent	Claims (check if ap		ABOVE CALO	TIT AT	ZIONS	=	\$280.00 \$1,528.00		
□ A	pplicar duced	nt clain by 1/2.	ns small entity statu		R 1.27). The fees indic				\$0.00		
						SUB	TOTAL	, =	\$1,528.00		
Process months	sing fee	of \$1. the ear	30.00 for furnishing liest claimed priority	g the English y date (37 Cl	translation later than FR 1.492 (f)).	□ 20			\$0.00		
					TOTAL NAT	IONAI	L FEE	=	\$1,528.00		
Fee for accomp	record panied	ing the	e enclosed assignme appropriate cover sh	ent (37 CFR 1 neet (37 CFR	.21(h)). The assignm 3.28, 3.31) (check if	ent must l applicabl	oe le).		\$0.00		
					TOTAL FEES	ENCL	OSED	=	\$1,528.00		
					•				Amount to be: refunded	\$	
a.	X	Δ ch	eck in the amount o	f \$1,52	3.00 to cover the	ahaya faa	a is analoss	<u>.</u>	charged	3	
ъ. ъ.		Pleas	se charge my Depos	it Account N	o	in the am		za.	to cover t	he above fees.	
c.	\boxtimes	The C		reby authoriz	ed to charge any addit				quired, or credit any	overpayment	
d.		Fees		a credit card	. WARNING: Inform	nation on t	this form m	ay bec			
NOTE	: Whe				on this form. Provident or 1.495				1		
1.137(2	a) or (b)) mus	st be filed and gran	ited to restoi	e the application to	pending s	status.			•	
			SPONDENCE TO:				(I)		Amas		
P.O. I	3ox 74	7	RT, KOLASCH & 1	BIRCH, LLI	•		SIGNAT	URE	y-viii-		
	Churcl 708-85		22040-0747		i .	Leonard R. Svensson					
							NAME				
							30,330				
							REGISTRATION NUMBER				
9							27 Dece	mber	2001		
							DATE				
/lmt						1					





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT COOPERATION TREATY

APPLICANT:

DALLE CARBONARE, Maurizio et al.

INTERNATIONAL

APPLN. NO.:

PCT/EP00/06087

U.S. APPLN. NO.:

NEW

FILING DATE:

28 December 2001

TITLE:

USE OF HYALURONIC ACID DERIVATIVES IN

PHARMACEUTICAL PREPARATIONS AND BIOMATERIALS FOR THE PREVENTION AND TREATMENT OF CUTANEOUS

SCARS

DOCKET:

2039-0156P

EXPRESS MAIL CERTIFICATE

DATE DEPOSITED: 28 December 2001

I hereby certify that the enclosed <u>Transmittal Letter to the United States</u> <u>Designated/Elected Office (DO/EO/US) Concerning A Filing Under 35 U.S.C. 371 and related documents</u> are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail Label No. EL501842213US

Date: 28 December 2001

Loti M. Tillman

Mailing Address:

Birch, Stewart, Kolasch & Birch, LLP P.O. Box 747 Falls Church, VA 22040-0747 (714) 708-8555